Roche’s Tecentriq Improves Survival in Ineligible NSCLC Patients

a professor at UCL, stated that these results are significant because they provide evidence that Tecentriq can be a viable treatment option for NSCLC patients who cannot tolerate platinum-based chemotherapy. Tecentriq is an immune checkpoint inhibitor that works by blocking the PD-L1 protein on cancer cells, allowing the body's immune system to recognize and attack the tumor. It has already been..

  • format_list_bulleted BS
  • · 2023. 7. 10.
  • textsms

Roche's Tecentriq Improves Survival in NSCLC Patients Ineligible for Platinum Chemo

Roche’s Tecentriq has been shown to improve survival in non-small cell lung cancer (NSCLC) patients who are not eligible for platinum-based doublet chemotherapy, according to data from the Phase III IPSOS trial. The study, led by University College London (UCL) and supported by Roche, revealed its findings in The Lancet. The results showed that patients treated with Tecentriq had a median overal..

  • format_list_bulleted BS
  • · 2023. 7. 8.
  • textsms

Roche and AbbVie to Compete with New Bispecific Antibodies for Lymphoma Market Share

Roche and AbbVie are set to compete in the lymphoma market with their newly approved bispecific antibodies (BsAbs). Four weeks after AbbVie's Epkinly was approved, the FDA has given its approval for Roche's Genentech's BsAb, Columvi. Both drugs will be available this summer, leading to a head-to-head competition between the two companies. These therapies utilize bispecific antibody design to bin..

  • format_list_bulleted BS
  • · 2023. 6. 19.
  • textsms

Merck Eyes Keytruda Indication Update with Phase III Gastric Cancer Data

Merck has announced that its blockbuster drug Keytruda met one of its primary endpoints in a Phase III trial for patients with esophageal cancer. The results are an important step toward full approval of the drug for this indication. Merck is now working with the FDA to update the current indication for Keytruda "to those patients whose tumors are PD-L1 positive" following positive results from ..

  • format_list_bulleted BS
  • · 2023. 6. 19.
  • textsms

Roche's Cerebrospinal Fluid Assays Approved in Canada for Alzheimer's Diagnosis

Roche Diagnostics Corporation has gained approval from Health Canada for its Cerebrospinal Fluid (CSF) assays to measure three biomarkers in adults aged 55 and over, allowing physicians to diagnose Alzheimer's disease. The Elecsys® beta-Amyloid, Phospho-Tau(181P), and Total-Tau CSF tests can be carried out on automated immunoassay analyzers available across the country. These biomarkers help tra..

  • format_list_bulleted BS
  • · 2023. 6. 9.
  • textsms